Deutsche Bank initiated coverage on Neurocrine Biosciences with a new price target
$NBIX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Deutsche Bank initiated coverage of Neurocrine Biosciences with a rating of Hold and set a new price target of $138.00